Skip to search formSkip to main contentSkip to account menu

0.8 ML adalimumab 50 MG/ML Injection [Humira]

Known as: 0.8 ML Humira 40 MG Injection, ADALIMUMAB 40 mg in 0.8 mL SUBCUTANEOUS INJECTION, SOLUTION [Humira], 0.8 ML Humira 50 MG/ML Injection 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Quality by design (QbD) is an efficient but challenging approach for the development of biosimilar due to the complex… 
2020
2020
Anti-drug antibodies (ADAs), specific for biotherapeutic drugs, are associated with reduced serum drug levels and compromised… 
2020
2020
Quality by design (QbD) is an efficient but challenging approach for the development of biosimilar due to the complex… 
2017
2017
The management of chronic inflammatory diseases, such as inflammatory bowel disease, psoriasis, and rheumatoid arthritis has… 
2016
2016
ABSTRACT Biosimilars are biological products that are highly similar to existing products approved by health authorities… 
2014
2014
Background TNFα inhibitors are highly effective drugs for the treatment of inflammatory disorders such as rheumatoid arthritis…